The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Non-Alcoholic Steatohepatitis Biomarkers Market At The End Of The 2026–2030 Forecast Period?
In recent years, the non-alcoholic steatohepatitis biomarkers market has experienced substantial growth. This market is projected to expand from $1.68 billion in 2025 to $2.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.2%. Historically, this expansion has been driven by factors such as the increasing occurrence of metabolic disorders, a rise in obesity and type 2 diabetes cases, the proliferation of liver disease research initiatives, the introduction of sophisticated diagnostic assays, and heightened pharmaceutical investment in NASH treatments.
The market size for non-alcoholic steatohepatitis biomarkers is projected to experience substantial growth in the coming years. This market is expected to reach $4.6 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 22.0%. The expansion during the forecast period is attributed to several factors, including increasing investments in precision hepatology, rising demand for non-invasive diagnostic tools, the broadening of biomarker-driven clinical trials, a growing adoption of personalized medicine approaches, and an increasing focus on early-stage disease management. Key trends for the forecast period encompass the accelerated development of non-invasive diagnostic biomarkers, a greater utilization of serum-based NASH biomarkers, the increasing integration of artificial intelligence in biomarker analysis, the expansion of companion diagnostics in drug development, and an enhanced focus on early disease detection.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
What Primary Drivers Are Shaping The Development Of The Non-Alcoholic Steatohepatitis Biomarkers Market?
The increasing occurrence of liver cancer is anticipated to propel the expansion of the non-alcoholic steatohepatitis biomarkers market going forward. Liver cancer involves the formation of malignant tumors within the liver, originating either within the liver itself (primary liver cancer) or spreading to it from other bodily regions (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are employed in liver cancer for various applications, including early detection, monitoring disease progression, assessing treatment response, providing prognostic information, and potentially reducing the necessity for invasive procedures. For instance, in July 2025, according to the ecancer medical science, a UK-based cancer journal, prior projections suggest that new liver cancer cases are expected to nearly double from 870,000 in 2022 to 1.52 million by 2050. This increase is primarily due to population growth and ageing, with the most significant rises projected in Africa. Liver cancer deaths are also forecasted to rise from 760,000 in 2022 to 1.37 million by 2050. Consequently, the growing prevalence of liver cancer is acting as a key driver for the growth of the non-alcoholic steatohepatitis biomarkers market.
What Segment Types Make Up The Non-Alcoholic Steatohepatitis Biomarkers Market?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Which Market Trends Are Creating New Opportunities In The Non-Alcoholic Steatohepatitis Biomarkers Market?
Leading companies within the non-alcoholic steatohepatitis biomarkers market are adopting advanced biomarker-platform technologies, such as multi-analyte fibrosis-scoring assays, to improve non-invasive disease assessment and the stratification of patient risk. These particular assays detect multiple proteins linked to fibrosis from a single blood sample, employing an algorithm to produce a numerical score that facilitates prognostic evaluation and aids in detecting advanced fibrosis. For example, in July 2023, Siemens Healthineers, a medical-technology company based in Germany, obtained breakthrough device designation from the US Food and Drug Administration for its Enhanced Liver Fibrosis Test. This multi-analyte fibrosis-scoring assay is designed to assist in identifying advanced fibrosis and cirrhosis in individuals with non-alcoholic fatty liver disease, utilizing a numerical score derived from three direct fibrosis biomarkers. The test contributes to earlier clinical assessment of liver disease severity and diminishes the need for invasive biopsy procedures.
Who Are The Key Players Driving Competition In The Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
Read the full non-alcoholic steatohepatitis biomarkers market report here:
How Does The Non-Alcoholic Steatohepatitis Biomarkers Market Perform Across Major Global Regions?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Alcoholic Steatohepatitis Biomarkers Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Fatty Liver Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model